142 related articles for article (PubMed ID: 34649152)
1. HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway.
Cao F; Xiao Z; Chen S; Zhao C; Chen D; Haisma HJ; Dekker FJ
Bioorg Chem; 2021 Dec; 117():105396. PubMed ID: 34649152
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
3. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
Sun Y; Bao X; Ren Y; Jia L; Zou S; Han J; Zhao M; Han M; Li H; Hua Q; Fang Y; Yang J; Wu C; Chen G; Wang L
Cell Death Dis; 2019 May; 10(6):400. PubMed ID: 31127087
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC.
Bao X; Sun Y; Bao C; Zhang J; Zou S; Yang J; Wu C; Wang L; Chen G
Bioorg Chem; 2019 May; 86():696-704. PubMed ID: 30831531
[TBL] [Abstract][Full Text] [Related]
5. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM
Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078
[TBL] [Abstract][Full Text] [Related]
6. Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer.
Mawhinney L; Armstrong ME; O' Reilly C; Bucala R; Leng L; Fingerle-Rowson G; Fayne D; Keane MP; Tynan A; Maher L; Cooke G; Lloyd D; Conroy H; Donnelly SC
Mol Med; 2015 Apr; 20(1):729-35. PubMed ID: 25826675
[TBL] [Abstract][Full Text] [Related]
7. Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Shindo Y; Arai W; Konno T; Kohno T; Kodera Y; Chiba H; Miyajima M; Sakuma Y; Watanabe A; Kojima T
Histochem Cell Biol; 2021 Jun; 155(6):637-653. PubMed ID: 33974136
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
9. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
10. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
Wang J; Zhou P; Wang X; Yu Y; Zhu G; Zheng L; Xu Z; Li F; You Q; Yang Q; Zhuo W; Sun J; Chen Z
Cell Prolif; 2019 May; 52(3):e12592. PubMed ID: 30848009
[TBL] [Abstract][Full Text] [Related]
11. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
12. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors.
Qian Y; Zhou S; Li J; Ma M; Chen H; Cao Y; Zhang Y; Sun C; Li K; Liu Y; Dai S; Ao M; Fang M; Wu Z; Li M
Eur J Pharmacol; 2023 Dec; 960():176114. PubMed ID: 37863412
[TBL] [Abstract][Full Text] [Related]
14. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
[TBL] [Abstract][Full Text] [Related]
15. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
16. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of MIF-rpS3 complex and sequential NF-κB activation is involved in IR-induced metastatic conversion of NSCLC.
Youn H; Son B; Kim W; Jun SY; Lee JS; Lee JM; Kang C; Kim J; Youn B
J Cell Biochem; 2015 Nov; 116(11):2504-16. PubMed ID: 25900216
[TBL] [Abstract][Full Text] [Related]
18. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
19. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
Zito CR; Jilaveanu LB; Anagnostou V; Rimm D; Bepler G; Maira SM; Hackl W; Camp R; Kluger HM; Chao HH
PLoS One; 2012; 7(2):e31331. PubMed ID: 22355357
[TBL] [Abstract][Full Text] [Related]
20. Blocking the MIF-CD74 axis augments radiotherapy efficacy for brain metastasis in NSCLC via synergistically promoting microglia M1 polarization.
Liu L; Wang J; Wang Y; Chen L; Peng L; Bin Y; Ding P; Zhang R; Tong F; Dong X
J Exp Clin Cancer Res; 2024 Apr; 43(1):128. PubMed ID: 38685050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
